Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus (HBV) DNA replication is a unique process involving reverse transcription of an RNA intermediate. It begins with the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA) in the hepatocyte nucleus. The cccDNA serves as a template for viral mRNA synthesis, including pregenomic RNA (pgRNA). The pgRNA is reverse transcribed by the viral polymerase into rcDNA within newly formed nucleocapsids. This replication cycle ensures persistent infection and virion production. Approved antiviral drugs primarily target the reverse transcriptase activity, inhibiting viral DNA synthesis but not eliminating the cccDNA reservoir.
Inhibition of reverse transcriptase activity
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus DNA replication (HBV DNA replication).